Key result
Rotavirus vaccine cuts hospitalizations ~50%, guiding serological immunity research for future norovirus and sapovirus vaccines.
Why the study?
Elucidating the determinants, breadth, and duration of serological antibody immunity and host genetic susceptibility factors to high-burden acute gastroenteritis viruses is essential to inform future vaccine development.
This review highlights the current understanding of humoral immunity following natural infection with major gastrointestinal viruses to guide future vaccine development.
Rotavirus vaccine success may guide norovirus and sapovirus strategies; leaves open serological correlates pending prospective validation.
Acute gastroenteritis (AGE) is a major cause of morbidity and mortality worldwide, resulting in an estimated 440,571 deaths of children under age 5 annually. Rotavirus, norovirus, and sapovirus are leading causes of childhood AGE. A successful rotavirus vaccine has reduced rotavirus hospitalizations by more than 50%. Using rotavirus as a guide, elucidating the determinants, breath, and duration of serological antibody immunity to AGE viruses, as well as host genetic factors that define susceptibility is essential for informing development of future vaccines and improving current vaccine candidates. Here, we summarize the current knowledge of disease burden and serological antibody immunity following natural infection to inform further vaccine development for these three high-burden viruses.
No takes yet. Share an insight, caveat, or question.
Zweigart et al. (2021) conducted a review in Acute gastroenteritis. A successful rotavirus vaccine has reduced rotavirus hospitalizations by more than 50%, providing a guide to elucidate serological immunity for future norovirus and sapovirus vaccines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: